ProLynx
San Francisco
About ProLynx
ProLynx is a biotechnology company that develops proprietary drug-delivery technologies designed to extend the half-life of therapeutic molecules, including peptides, proteins, and small molecules, so they maintain effective levels in the body for controlled periods. The company’s core platform uses ╬▓-eliminative linkers that are programmed to release native drugs from macromolecular carriers (such as circulating polymers or hydrogel microspheres) at predictable rates, enabling sustained release over weeks to months. ProLynx applies this technology to create long-acting therapeutic candidates and partners with pharmaceutical firms and academic researchers to design and test novel drug conjugates. Its pipeline includes extended-duration therapies for metabolic and obesity indications, with a focus on formulations engineered for monthly or quarterly dosing schedules.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $72.3M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2025)
- Website: prolynxinc.com
- Phone: +1 415-552-5306
Industries & Categories
Biotechnology, Health Care, Manufacturing, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/prolynx-57749 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.